Suppr超能文献

C-C 基序趋化因子 2-C-C 趋化因子受体 2 阻断剂(包括普罗加曼)作为抗癌剂的潜力。

Potentials of C-C motif chemokine 2-C-C chemokine receptor type 2 blockers including propagermanium as anticancer agents.

机构信息

Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.

Department of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.

出版信息

Cancer Sci. 2019 Jul;110(7):2090-2099. doi: 10.1111/cas.14075. Epub 2019 Jun 10.

Abstract

Inflammation plays an essential role in the development and progression of most cancers. Chemokine C-C motif chemokine 2 (CCL2) and its receptor C-C chemokine receptor type 2 (CCR2) constitute a key signaling axis in inflammation that has recently attracted much interest on the basis of evidence showing its association with cancer progression. Propagermanium (3-oxygermylpropionic acid polymer) is an organogermanium compound that is given for the treatment of hepatitis B in Japan and which inhibits the CCL2-CCR2 signaling pathway. Herein, we review the importance of the CCL2-CCR2 axis as a target in cancer treatment as shown by studies in mice and humans with pharmacological agents including propagermanium.

摘要

炎症在大多数癌症的发生和发展中起着至关重要的作用。趋化因子 C-C 基序趋化因子 2(CCL2)及其受体 C-C 趋化因子受体 2(CCR2)构成了炎症中的一个关键信号轴,最近基于其与癌症进展相关的证据,引起了广泛关注。Propagermanium(3-氧代锗丙酸聚合物)是一种有机锗化合物,在日本用于治疗乙型肝炎,可抑制 CCL2-CCR2 信号通路。本文综述了趋化因子 CCL2-CCR2 轴作为癌症治疗靶点的重要性,包括 Propagermanium 在内的药理学药物在小鼠和人类研究中的结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfbb/6609805/4f01a33e5e64/CAS-110-2090-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验